Now is the time for investors to take profits in Biogen, says Jim Cramer

CNBC's Jim Cramer and the 'Squawk on the Street' team discuss shares of Biogen, which are soaring in pre-market trading after the company reported positive results from a late-stage Alzheimer's drug study.